Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Lixiana (Atrial Fibrillation) - Analysis and Forecasts to 2022
Market Briefing
Published: May 2012
Pages: 38
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 1250.00 Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Indication Areas
Lixiana (Atrial Fibrillation) - Analysis and Forecasts to 2022
Summary
GlobalData?s pharmaceuticals report, ?Lixiana (Atrial Fibrillation) - Analysis and Forecasts to 2022? provides Lixiana global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData?s proprietary databases, primary and secondary research using Company?s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Lixiana including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Lixiana including efficacy, safety, pricing, competition and other details which influence its sales potential
- Global sales forecast for 2014-2022 for Lixiana
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug?s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets
Keywords
Lixiana, edoxaban, direct oral Factor Xa inhibitor, venous thromboembolism, stroke and systemic embolic events, atrial fibrillation, recurrent venous thromboembolism, deep vein thrombosis, pulmonary embolisms
Summary
GlobalData?s pharmaceuticals report, ?Lixiana (Atrial Fibrillation) - Analysis and Forecasts to 2022? provides Lixiana global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData?s proprietary databases, primary and secondary research using Company?s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Lixiana including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Lixiana including efficacy, safety, pricing, competition and other details which influence its sales potential
- Global sales forecast for 2014-2022 for Lixiana
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug?s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets
Keywords
Lixiana, edoxaban, direct oral Factor Xa inhibitor, venous thromboembolism, stroke and systemic embolic events, atrial fibrillation, recurrent venous thromboembolism, deep vein thrombosis, pulmonary embolisms